Basic Stats
| CIK | 1701541 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Black Diamond Therapeutics, Inc.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction of incorporation) (Co |
|
| August 7, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 BLAC |
|
| August 7, 2025 |
Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update •Enrollment completed for the Phase 2 trial of silevertinib (BDTX-1535) in 1L patients with non-classical EGFRm NSCLC (n=43); ORR and preliminary DOR data on track for Q4 2025 •Exploring partnership opportunities to advance pivotal development of silevertinib in NSCLC and GBM •Plan to meet with FDA regarding 1L NSCLC development path in 1H 2026, when PFS data becomes available •Cash, cash equivalents, and investments of $142. |
|
| June 12, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction (Commission (I.R.S. Em |
|
| May 12, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 BLA |
|
| May 12, 2025 |
Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***]”. LICENSE AGREEMENT by and between BLACK DIAMOND THERAPEUTICS, INC. and SERVIER PHARMACEUTICALS LLC March 1 |
|
| May 12, 2025 |
Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update •Clinical data on track for Q4 2025 from Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC •Expansion of investigator sponsored Phase 0/1 trial into newly diagnosed glioblastoma patients with EGFR alterations initiated in Q1 2025 •Cash, cash equivalents, and investments of $152. |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction of incorporation) (Comm |
|
| April 18, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| April 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| March 19, 2025 |
Exhibit 99.2 1 Black Diamond Therapeutics, Inc. Developing MasterKey Therapies to Defeat Cancer Resistance March 19, 2025 2 Forward - Looking Statements This presentation contains forward looking statements of Black Diamond Therapeutics, Inc (“we,” “us,” “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward looking statements include all statements that are no |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction (Commission (I.R.S. E |
|
| March 19, 2025 |
Exhibit 99.1 Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy · The partnership underscores Servier’s commitment to developing targeted therapies that address unmet medical needs in oncology · Servier will develop and commercialize BDTX-4933, a Phase 1 asset with best-in-class potential targeting both RAS mutations and RAF altera |
|
| March 6, 2025 |
As filed with the Securities and Exchange Commission on March 6, 2025 As filed with the Securities and Exchange Commission on March 6, 2025 Registration No. |
|
| March 6, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 BLACK DI |
|
| March 6, 2025 |
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update •Clinical data on track for Q2 2025 in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC •Expansion of investigator sponsored “window of opportunity” trial into newly diagnosed glioblastoma patients with EGFR aberrations expected in Q1 2025 •Cash, cash equivalents, and investments of $98. |
|
| March 6, 2025 |
Black Diamond Therapeutics, Inc. Insider Trading Policy Exhibit 19 BLACK DIAMOND THERAPEUTICS, INC. THIRD AMENDED AND RESTATED INSIDER TRADING POLICY Black Diamond Therapeutics, Inc. (together with its subsidiary, the “Company”) has adopted the following policy and procedures for securities trading by the Company’s directors, officers, employees and designated consultants and contractors. This Third Amended and Restated Insider Trading Policy (as may b |
|
| March 6, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction of incorporation) (Com |
|
| March 6, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Black Diamond Therapeutics, Inc. |
|
| November 14, 2024 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 p24-3219exhibit991.htm JOINT ACQUISITION STATEMENT EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity |
|
| November 14, 2024 |
SC 13G 1 p24-3219sc13g.htm BLACK DIAMOND THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Black Diamond Therapeutics, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 09203E105 (CUSIP Number) September 30, 2024 (Date of event which requires filing of th |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2024 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction of incorporation) ( |
|
| November 5, 2024 |
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update •Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad spectrum of classical, non-classical, and C797S resistance mutations in September 2024 •Presented real-world treatment practices and patient outcomes in newly diagnosed NSCLC patients with non-classical EGFR mutations at the 2024 ESMO Congress •Clinical updates of BDTX-1535 in EGFRm NSCLC and regulatory feedback expected in Q1 2025 •Cash, cash equivalents, and investments of $112. |
|
| November 5, 2024 |
October 4, 2024 Fang Z. Ni, Pharm.D. Re: Notice of Termination and Separation Agreement Dear Fang: Pursuant to Section 4 of the Employment Agreement (the “Employment Agreement”) between you and Black Diamond Therapeutics, Inc., a Delaware corporation (the “Company”), this letter will serve as notice of termination of your employment, effective October 7, 2024 (the “Separation Date”). Your employme |
|
| November 5, 2024 |
EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between Black Diamond Therapeutics, Inc. |
|
| November 5, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 |
|
| October 7, 2024 |
Exhibit 99.1 Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway Company advancing BDTX-1535 in EGFRm NSCLC towards key inflection points in Q1 2025 Will deprioritize BDTX-4933 and seek potential partners Anticipated cost savings expected to extend cash runway into Q2 2026 CAMBRIDGE, Mass., October 07, 2024 (GLOBE NEWSWIRE) – Black Diamond |
|
| October 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2024 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction (Commission (I.R.S. |
|
| September 23, 2024 |
Exhibit 99.1 Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations BDTX-1535 dose of 200 mg daily selected for pivotal development; favorable tolerability profile and no new safety signals observed Preliminary |
|
| September 23, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2024 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction (Commission (I.R. |
|
| August 8, 2024 |
SC 13D/A 1 d807664dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 6)* Black Diamond Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Sec |
|
| August 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction of incorporation) (Co |
|
| August 6, 2024 |
Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update •Initial Phase 2 data of BDTX-1535 in 2L/3L patients with EGFRm NSCLC on track for later in Q3 2024 •On track to announce initial Phase 2 data of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC in Q1 2025, and initial Phase 1 data of BDTX-4933 in KRASm NSCLC in Q4 2024 •Upcoming poster presentation at 2024 ESMO Congress in September, titled “Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients with Non-classical EGFR Mutations Demonstrates High Unmet Medical Need” •Cash, cash equivalents, and investments of $123. |
|
| August 6, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 BLAC |
|
| June 6, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BLACK DIAMOND THERAPEUTICS, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Black Diamond Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The Co |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction (Commission (I.R.S. Emp |
|
| May 13, 2024 |
SC 13D/A 1 nea16-bldiamond18839.htm NEW ENTERPRISE ASSOCIATES 16, L.P. / BLACK DIAMOND THERAPEUTICS, INC. - SCHEDULE 13D/A(#1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Black Diamond Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 09203E105 (CUS |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction of incorporation) (Commi |
|
| May 9, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 BLA |
|
| May 9, 2024 |
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update •Initial Phase 2 data of BDTX-1535 in 2L/3L EGFRm NSCLC patients on track for Q3 2024 •Enrollment ongoing in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC; initial data expected Q1 2025 •Presented real world evidence on the evolving EGFR mutation landscape in NSCLC, and the potential of BDTX-1535 across multiple lines of therapy at the 2024 AACR annual meeting •Poster presentations upcoming June 1st at 2024 ASCO Annual Meeting on BDTX-1535 in GBM patients: Phase 1 dose-escalation data and initial “window of opportunity” trial results •Cash, cash equivalents, and investments of $115. |
|
| May 9, 2024 |
BDTX / Black Diamond Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment SC 13D/A 1 tm2414095d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Black Diamond Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 09203E105 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Bo |
|
| April 24, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 12, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| April 11, 2024 |
Black Diamond Therapeutics Announces Changes to Board of Directors Exhibit 99.1 Black Diamond Therapeutics Announces Changes to Board of Directors CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) – Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancers, today announced that industry veterans Shannon Campbell and Prakash Raman, Ph.D., ha |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2024 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction (Commission (I.R.S. E |
|
| March 12, 2024 |
Black Diamond Therapeutics, Inc. Compensation Recovery Policy BLACK DIAMOND THERAPEUTICS, INC. COMPENSATION RECOVERY POLICY Adopted as of October 2, 2023 Black Diamond Therapeutics, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Pers |
|
| March 12, 2024 |
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update •Dosed first patient in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC •Clinical data on track for Q3 2024 in Phase 2 trial of BDTX-1535 in 2L/3L patients with acquired resistance or non-classical EGFRm NSCLC •Oral presentation at AACR annual meeting in Apr |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction of incorporation) (Co |
|
| March 12, 2024 |
Amended and Restated By-laws of the Registrant SECOND AMENDED AND RESTATED BY-LAWS OF BLACK DIAMOND THERAPEUTICS, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1.Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by or in the manner determined by the Board of Directo |
|
| March 12, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Black Diamond Therapeutics, Inc. |
|
| March 12, 2024 |
As filed with the Securities and Exchange Commission on March 12, 2024 As filed with the Securities and Exchange Commission on March 12, 2024 Registration No. |
|
| March 12, 2024 |
2020 Employee Stock Purchase Plan, as amended BLACK DIAMOND THERAPEUTICS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Black Diamond Therapeutics, Inc. 2020 Employee Stock Purchase Plan (as may be amended and/or restated from time to time, the “Plan”) is to provide eligible employees of Black Diamond Therapeutics, Inc., a Delaware corporation (the “Company”), and each Designated Company (as defined in Section 11) with opportuniti |
|
| March 12, 2024 |
Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED The common stock, par value $0.0001 per share (“Common Stock”) of Black Diamond Therapeutics, Inc. (the “Company,” “we,” “us,” and “our”) is registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The following |
|
| March 12, 2024 |
Subsidiaries of the Registrant Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation Black Diamond Therapeutics Security Corporation Massachusetts |
|
| March 12, 2024 |
Employment Agreement between the Registrant and Melanie Morrison EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between Black Diamond Therapeutics, Inc. |
|
| March 12, 2024 |
Amended and Restated Non-Employee Director Compensation Plan, effective February 14, 2024 BLACK DIAMOND THERAPEUTICS, INC. FIFTH AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Black Diamond Therapeutics, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are |
|
| March 12, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 BLACK DI |
|
| February 13, 2024 |
BDTX / Black Diamond Therapeutics, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d771535dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Black Diamond Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09203E105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing This Statement) Check the appropriate box |
|
| January 18, 2024 |
The UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2024 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction (Commission (I. |
|
| January 4, 2024 |
The UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction (Commission (I.R |
|
| January 4, 2024 |
Exhibit 99.1 Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones FDA feedback on BDTX-1535 enables initiation of Phase 2 cohort in first-line treatment of non-classical EGFR mutant NSCLC Fast Track Designation granted for BDTX-1535 as second-line treatment for EGFR mutant/C797S NSCLC BDTX-1535 Phase 2 results for 2L/3L patients with EGFR mutant NSCLC expected Q3 2024 |
|
| January 4, 2024 |
Exhibit 99.2 1 Black Diamond Therapeutics, Inc. Developing MasterKey Therapies to Defeat Cancer Resistance January 2024 2 Forward - Looking Statements Statements contained in this presentation regarding matters that are not historical facts are “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 . Because such statements are subject to risks an |
|
| December 13, 2023 |
Exhibit 99.1 Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM Initial results show promising clinical activity in heavily pretreated patients 22 patients evaluable for efficacy: 3 patients on therapy longer than 10 months, 1 patient longer than 6 months, and 5 patients longer than 4 months 19 patients with measurabl |
|
| December 13, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events The UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2023 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction (Commission (I |
|
| November 9, 2023 |
SC 13D/A 1 d473224dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 5)* Black Diamond Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Sec |
|
| November 6, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 |
|
| November 6, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction of incorporation) ( |
|
| November 6, 2023 |
Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update •Presented BDTX-1535 Phase 1 dose escalation data showing durable anti-tumor activity and favorable safety profile in NSCLC patients across heterogeneous EGFR mutations at the October 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics •BDTX-1535 NSCLC expansion cohorts enrolling, initial data expected in 2024 •BDTX-1535 Phase 1 dose escalation data in GBM expected later this year •Dosed first patient in a Phase 1 trial of BDTX-4933, a brain-penetrant RAF inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors •Cash, cash equivalents, and investments of $144. |
|
| September 18, 2023 |
Exhibit 10.2 EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between Black Diamond Therapeutics, Inc., a Delaware corporation (the “Company”), and Mark Velleca (the “Executive”) and is effective as of Executive’s first date of employment with the Company (the “Effective Date”). WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the |
|
| September 18, 2023 |
Exhibit 10.1 September 17, 2023 David M. Epstein, PhD Re: Notice of Termination and Separation Agreement Dear David: Pursuant to Section 4 of the Employment Agreement (the “Employment Agreement”) between you and Black Diamond Therapeutics, Inc., a Delaware corporation (the “Company”), this letter will serve as notice of termination of your employment, effective September 15, 2023 (the “Separation |
|
| September 18, 2023 |
Exhibit 99.1 Black Diamond Therapeutics Announces CEO Transition Current Chairman of the Board and industry veteran Mark Velleca appointed CEO CAMBRIDGE, Mass. and NEW YORK, Sept. 18, 2023 (GLOBE NEWSWIRE) - Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing therapies that target families of oncogenic mutations in patients with genetically defin |
|
| September 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2023 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction (Commission (I.R. |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction of incorporation) (C |
|
| August 11, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 BLAC |
|
| August 11, 2023 |
Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update •Announced initial clinical data from dose-escalation portion of Phase 1 clinical trial of BDTX-1535, an EGFR MasterKey inhibitor, demonstrating a favorable tolerability profile and clinical proof of activity based on radiographic tumor responses and circulating tumor DNA changes in NSCLC patient |
|
| June 30, 2023 |
15,000,000 Shares of Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-268341 PROSPECTUS SUPPLEMENT (To Prospectus dated November 14, 2022) 15,000,000 Shares of Common Stock We are offering 15,000,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Select Market under the symbol “BDTX.” On June 28, 2023, the closing price of our common stock, as reported on the Nasda |
|
| June 30, 2023 |
Exhibit 1.1 BLACK DIAMOND THERAPEUTICS, INC. 15,000,000 Shares of Common Stock Underwriting Agreement June 29, 2023 PIPER SANDLER & CO. As Representative of the several Underwriters named in Schedule 1 hereto c/o Piper Sandler & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: Black Diamond Therapeutics, Inc., a Delaware corporation (the “Company”), prop |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2023 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction (Commission (I.R.S. Em |
|
| June 29, 2023 |
Subject to Completion Preliminary Prospectus Supplement dated June 29, 2023 TABLE OF CONTENTS The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2023 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction (Commission (I.R.S. Em |
|
| June 27, 2023 |
Exhibit 99.1 Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families · BDTX-1535, an epidermal growth factor receptor (EGFR) MasterKey inhibitor, demonstrates clinical proof of activity for MasterKey mutation-targeting approach based on radiographic tumor responses |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 Black Diamond Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction (Commission (I. |
|
| May 9, 2023 |
Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update •On track to provide clinical update from dose-escalation portion of Phase 1 clinical trial of EGFR MasterKey inhibitor BDTX-1535 in the second half of 2023; Dose Expansion cohorts expected to open in 2023 •FDA clearance of IND application for BDTX-4933, RAF MasterKey inhibitor; Anticipate first patient dosing in the second quarter of 2023 •Announces nomination of development candidate, BDTX-4876, for FGFR 2/3 selective inhibitor program; Company to evaluate strategic alternatives for this program •Cash, cash equivalents, and investments of $103. |
|
| May 9, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 BLA |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction of incorporation) (Commi |
|
| April 4, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permit |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 9, 2023 |
As filed with the Securities and Exchange Commission on March 9, 2023 As filed with the Securities and Exchange Commission on March 9, 2023 Registration No. |
|
| March 9, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Black Diamond Therapeutics, Inc. |
|
| March 9, 2023 |
BLACK DIAMOND THERAPEUTICS, INC. FOURTH AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Black Diamond Therapeutics, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are |
|
| March 9, 2023 |
Employment Agreement between the Registrant and Elizabeth Montgomery EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between Black Diamond Therapeutics, Inc. |
|
| March 9, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 BLACK DI |
|
| March 9, 2023 |
EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made between Black Diamond Therapeutics, Inc. |
|
| March 9, 2023 |
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update •On track to provide clinical update from dose-escalation portion of Phase 1 clinical trial of EGFR MasterKey inhibitor BDTX-1535 in the second half of 2023 •FDA clearance of IND application for BDTX-4933 in the first quarter of 2023, a brain-penetrant RAF MasterKey inhibitor for the treatment of all-class RAF and RAS mutant tumors; initiation of Phase 1 clinical trial expected in the first half of 2023 •Presented new preclinical data demonstrating the potential of MasterKey programs BDTX-1535 and BDTX-4933 at the 34th EORTC-NCI-AACR Symposium •Cash, cash equivalents, and investments of $122. |
|
| March 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction of incorporation) (Com |
|
| February 14, 2023 |
BDTX / Black Diamond Therapeutics Inc / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Black Diamond Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09203E105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuan |
|
| February 14, 2023 |
EX-99.B Exhibit B POWER OF ATTORNEY The Undersigned, Hugo van Neutegem herewith gives Power of Attorney to Mrs. Nathalie M.A. Isidora-Kwidama, born in Curacao on, holder of a passport issued by the Kingdom of the Netherlands, with number, to represent the Company in the broadest sense of the word and in the best interest of the Company and further to do if were the Undersigned personally present. |
|
| December 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2022 (December 13, 2022) BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdictio |
|
| December 19, 2022 |
Black Diamond Therapeutics Announces Changes to Board of Directors Exhibit 99.1 Black Diamond Therapeutics Announces Changes to Board of Directors CAMBRIDGE, Mass. and NEW YORK, Dec. 19, 2022 (GLOBE NEWSWIRE) - Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that Chairman of the Board of Directors, Robert (Bob) A. Ingram, has stepped down due to |
|
| December 12, 2022 |
Exhibit 99.1 Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company - $30M Series A investment from Versant Ventures and NEA- CAMBRIDGE, Mass. and NEW YORK, December 12, 2022 (GLOBE NEWSWIRE) - Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of Maste |
|
| December 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2022 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction (Commission (I.R.S |
|
| November 18, 2022 |
CORRESP 1 filename1.htm VIA EDGAR November 18, 2022 United States Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Black Diamond Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-3 File No. 333-268341 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amen |
|
| November 14, 2022 |
As filed with the Securities and Exchange Commission on November 14, 2022 Table of Contents As filed with the Securities and Exchange Commission on November 14, 2022 Registration No. |
|
| November 14, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Black Diamond Therapeutics, Inc. |
|
| November 8, 2022 |
Black Diamond Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update •Presented new data at the 34th EORTC-NCI-AACR Symposium highlighting robust preclinical anti-tumor activity of BDTX-1535 and BDTX-4933 across multiple families of oncogenic mutations while sparing wild type; both MasterKey therapies demonstrate key attributes of next generation small molecule inh |
|
| November 8, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction of incorporation) ( |
|
| August 9, 2022 |
Black Diamond Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update ?Strengthened leadership team with appointment of Sergey Yurasov, M. |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction of incorporation) (Co |
|
| August 9, 2022 |
EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made between Black Diamond Therapeutics, Inc. |
|
| August 9, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 BLAC |
|
| June 7, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 Black Diamond Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction (Commission (I. |
|
| May 11, 2022 |
Black Diamond Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update ?Dosed first patient in Phase 1 Study of BDTX-1535 for the treatment of glioblastoma multiforme (GBM) and non-small cell lung cancer (NSCLC) including those with central nervous system (CNS) tumors; clinical update expected in 2023 ?Continued strategic focus on development of BDTX-1535, BDTX-4933 and MAP drug discovery engine enabled small molecule drug discovery efforts ?Financial position strengthened and cash runway extended into third quarter of 2024; cash, cash equivalents, and investments of approximately $179. |
|
| May 11, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 BLA |
|
| May 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction of incorporation) (Comm |
|
| May 11, 2022 |
Amended and Restated Non-Employee Director Compensation Plan. BLACK DIAMOND THERAPEUTICS, INC. THIRD AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the ?Policy?) of Black Diamond Therapeutics, Inc., a Delaware corporation (the ?Company?), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 28, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??) ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as |
|
| April 25, 2022 |
1 Black Diamond Therapeutics, Inc. Pioneering the Development of MasterKey Therapies APRIL 2022 Exhibit 99.2 1 Black Diamond Therapeutics, Inc. Pioneering the Development of MasterKey Therapies APRIL 2022 2 Important Notice and Disclaimers This presentation contains ?forward - looking statements? of Black Diamond Therapeutics, Inc . (?Black Diamond,? ?we? or ?our?) within the meaning of the Private Securities Litigation Reform Act of 1995 . These forward - looking statements include, but are |
|
| April 25, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2022 Black Diamond Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction (Commission ( |
|
| April 25, 2022 |
Black Diamond Therapeutics Announces Pipeline Prioritization and Workforce Realignment Exhibit 99.1 Black Diamond Therapeutics Announces Pipeline Prioritization and Workforce Realignment ? Strategic areas of focus on development of BDTX-1535 and BDTX-4933 as well as MAP platform enabled small molecule drug discovery efforts ? ? Company to discontinue development of BDTX-189 and reduce workforce to extend its cash runway into 3Q 2024, supporting execution of key milestones ? CAMBRIDG |
|
| April 14, 2022 |
BDTX / Black Diamond Therapeutics Inc / BB BIOTECH AG - SC 13G/A Passive Investment United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Black Diamond Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09203E105 (CUSIP Number) April 11, 2022 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| April 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2022 Black Diamond Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction (Commission (I |
|
| April 7, 2022 |
Black Diamond Therapeutics Appoints Wendy L. Dixon to its Board of Directors Exhibit 99.1 Black Diamond Therapeutics Appoints Wendy L. Dixon to its Board of Directors CAMBRIDGE, Mass. and NEW YORK, April 7, 2022 (GLOBE NEWSWIRE) - Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the appointment of Wendy L. Dixon, Ph.D., to its Board of Directors (the ?Boar |
|
| March 17, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 BLACK DI |
|
| March 17, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Black Diamond Therapeutics, Inc. |
|
| March 17, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2022 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction of incorporation) (Co |
|
| March 17, 2022 |
As filed with the Securities and Exchange Commission on March 17, 2022 As filed with the Securities and Exchange Commission on March 17, 2022 Registration No. |
|
| March 17, 2022 |
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update ?IND allowed by U. |
|
| February 11, 2022 |
BDTX / Black Diamond Therapeutics Inc / BB BIOTECH AG - SC 13G/A Passive Investment United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Black Diamond Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09203E105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| February 9, 2022 |
BDTX / Black Diamond Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Black Diamond Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 09203E105 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 10, 2022 |
Exhibit 99.2 1 Black Diamond Therapeutics, Inc. Pioneering the Development of MasterKey Therapies JANUARY 2022 2 Important Notice and Disclaimers This presentation contains ?forward-looking statements? of Black Diamond Therapeutics, Inc.(?Black Diamond,? ?we? or ?our?) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not |
|
| January 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 Black Diamond Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction (Commission |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 Black Diamond Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction (Commission |
|
| January 10, 2022 |
Exhibit 99.1 Black Diamond Therapeutics Announces Strategic Priorities and Expected Milestones for 2022 - Company announces IND submission for BDTX-1535 for the treatment of GBM and NSCLC including those with CNS tumors; - Company to enroll additional patients into MasterKey-01 Phase 1 safety expansion cohort to obtain more clinical data and inform future development of BDTX-189; - Company anticip |
|
| November 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2021 Black Diamond Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction (Commissio |
|
| November 8, 2021 |
Black Diamond Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update ?Black Diamond continues preparation for initiation of the Phase 2 portion of MasterKey-01 study of BDTX-189 this year ?Pre-clinical data from BDTX-1535, BRAF, and FGFR programs presented at AACR-NCI-EORTC (ANE) International Conference ?Strategic partnership established with OpenEye to accelerate drug discovery efforts through cloud-based molecular dynamics technology ?Cash, cash equivalents, and investments of $235. |
|
| November 8, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction of incorporation) ( |
|
| November 8, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction of incorporation) (C |
|
| August 12, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 BLAC |
|
| August 12, 2021 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (?Agreement?) is made between Black Diamond Therapeutics, Inc., a Delaware corporation (the ?Company?), and Elizabeth Buck, Ph.D. (the ?Executive?) and is effective as of August 11, 2021 (the ?Effective Date?). Except with respect to the Equity Documents (as defined below), this Agreement supersedes in all respects al |
|
| August 12, 2021 |
Black Diamond Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update ?Initial Phase 1 clinical PK, safety, and preliminary efficacy data for BDTX-189 presented at ASCO Annual Meeting; on track to initiate Phase 2 portion of MasterKey-01 study in second half of 2021 ?Pre-clinical data for BDTX-1535 presented at AACR Annual Meeting; program on track to enter the clinic in 2022 ?Early-stage pipeline programs targeting BRAF and FGFR remain on track for IND filing in 2022 ?Biotech industry veteran Mark Velleca, M. |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 Black Diamond Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction (Commission ( |
|
| August 10, 2021 |
Black Diamond Therapeutics Announces Appointment of Mark Velleca, M.D., Ph.D. to Board of Directors Exhibit 99.1 Black Diamond Therapeutics Announces Appointment of Mark Velleca, M.D., Ph.D. to Board of Directors CAMBRIDGE, Mass. and NEW YORK, August 10, 2021 (GLOBE NEWSWIRE) - Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, today announced the appointment of Mark A. Velleca, M |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 Black Diamond Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction (Commission ( |
|
| June 22, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2021 Black Diamond Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction (Commission (I |
|
| May 19, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2021 Black Diamond Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction (Commission (IR |
|
| May 19, 2021 |
Exhibit 99.1 Black Diamond Therapeutics Presents Phase 1 Pharmacokinetic, Safety, and Preliminary Efficacy Data of BDTX-189 in Advanced Solid Tumors Harboring EGFR or HER2 Alterations Once-daily (QD) dose escalation completed; pharmacokinetic (PK) profile consistent with design principles and preclinical predictions Generally well-tolerated with medically manageable toxicities observed; safety pro |
|
| May 7, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2021 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction of incorporation) (Commi |
|
| May 7, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 BLA |
|
| May 7, 2021 |
Black Diamond Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update ?Patient enrollment and dosing in the Phase 1/2 clinical trial of BDTX-189 continue to track in line with projections at initiation of the study, with dose-escalation portion on track to complete in first half of 2021; initial Phase 1 clinical pharmacokinetic (PK), safety, and preliminary efficacy |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 27, 2021 |
DEF 14A 1 tm2113779-1def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of t |
|
| April 21, 2021 |
Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2021 Black Diamond Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction of incorporat |
|
| March 25, 2021 |
Employment Agreement between the Registrant and Rachel Humphrey Exhibit 10.11 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made between Black Diamond Therapeutics, Inc., a Delaware corporation (the ?Company?), and Rachel Humphrey, M.D. (the ?Executive?) and is effective as of September 8, 2020 (the ?Effective Date?). This Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject mat |
|
| March 25, 2021 |
As filed with the Securities and Exchange Commission on March 25, 2021 Registration No. |
|
| March 25, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 BLACK DI |
|
| March 25, 2021 |
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update ?Patient enrollment and dosing in the Phase 1/2 clinical trial of BDTX-189 continue to track in line with projections at initiation of the study, with dose-escalation portion on track to complete in first half of 2021; initiation of safety expansion cohort anticipated in the second |
|
| March 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2021 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction of incorporation) (Co |
|
| March 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2021 Black Diamond Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction of incorporat |
|
| February 11, 2021 |
SC 13G United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Black Diamond Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 09203E105 (CUSIP Number) February 3, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Black Diamond Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 09203E105 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13 |
|
| February 1, 2021 |
Form of Senior Indenture between Registrant and one or more trustees to be named EX-4.3 Exhibit 4.3 BLACK DIAMOND THERAPEUTICS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 202[●] Senior Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and |
|
| February 1, 2021 |
Form of Subordinated Indenture between Registrant and one or more trustees to be named EX-4.4 Exhibit 4.4 BLACK DIAMOND THERAPEUTICS, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 202[●] Subordinated Debt Securities TABLE OF CONTENTS(1) Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities a |
|
| February 1, 2021 |
S-3ASR Table of Contents As filed with the Securities and Exchange Commission on February 1, 2021 Registration No. |
|
| February 1, 2021 |
Entry into a Material Definitive Agreement - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2021 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction of incorporatio |
|
| February 1, 2021 |
Open Market Sale AgreementSM, dated as of February 1, 2021, between the Registrant and Jefferies LLC Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM February 1, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Black Diamond Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company |
|
| January 20, 2021 |
EX-99.1 Exhibit 99.1 Black Diamond Therapeutics Announces Appointment of Oncology Clinical Development Veteran Dr. Kapil Dhingra to Board of Directors CAMBRIDGE, Mass. and NEW YORK, January 20, 2021 – Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the appoin |
|
| January 20, 2021 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2021 (January 19, 2021) BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdict |
|
| December 3, 2020 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 4)* Black Diamond Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 09203E105 (CUSIP Numb |
|
| November 23, 2020 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3)* Black Diamond Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 09203E105 (CUSIP Numb |
|
| November 10, 2020 |
Black Diamond Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update •Continued to enroll and dose patients in Phase 1/2 clinical trial of BDTX-189, with Phase 1 portion on track to complete by first half of 2021 •Strengthened Board of Directors with appointment of Robert A. |
|
| November 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2020 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction of incorporation) |
|
| November 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 |
|
| September 29, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2020 (September 25, 2020) Black Diamond Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or oth |
|
| September 29, 2020 |
EX-99.1 Exhibit 99.1 Black Diamond Therapeutics Announces the Appointment of Biopharmaceutical Veteran Robert A. Ingram as Chairman of the Board CAMBRIDGE, Mass. and NEW YORK, September 29, 2020 – Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the appointmen |
|
| September 25, 2020 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)* Black Diamond Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 09203E105 (CUSIP Numb |
|
| August 21, 2020 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* Black Diamond Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 09203E105 (CUSIP Numb |
|
| August 11, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2020 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction of incorporation) (C |
|
| August 11, 2020 |
Exhibit 10.1 11/02 SOG(BY)-INS Revised 12/05 LEASE RREEF AMERICA REIT II CORP. PPP, Landlord, and BLACK DIAMOND THERAPEUTICS, INC., Tenant Riverfront Office Park Cambridge, Massachusetts Table of Contents Page 1. USE AND RESTRICTIONS ON USE 1 2. TERM 4 3. RENT 6 4. RENT ADJUSTMENTS 6 5. SECURITY DEPOSIT 9 6. ALTERATIONS 11 7. REPAIR 12 8. LIENS 12 9. ASSIGNMENT AND SUBLETTING 12 10. INDEMNIFICATIO |
|
| August 11, 2020 |
Black Diamond Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update •Obtained U. |
|
| August 11, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 BLAC |
|
| May 12, 2020 |
Black Diamond Therapeutics Reports First Quarter 2020 Financial Results and Corporate Update Black Diamond Therapeutics Reports First Quarter 2020 Financial Results and Corporate Update •Cash and cash equivalents of $357. |
|
| May 12, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 BLA |
|
| May 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2020 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction of incorporation) (Comm |
|
| March 24, 2020 |
Exhibit 4.4 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED The common stock, par value $0.0001 per share (“Common Stock”) of Black Diamond Therapeutics, Inc. (the “Company,” “we,” “us,” and “our”) is registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The following |
|
| March 24, 2020 |
BDTX / Black Diamond Therapeutics, Inc. 10-K - Annual Report - 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-38501 BLACK DI |
|
| March 24, 2020 |
Exhibit 10.13 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. AMENDMENT NO. 3 TO SERVICES AGREEMENT This AMENDMENT NO. 3 TO SERVICES AGREEMENT, effective as of April 1, 2020 (this “Amendme |
|
| March 24, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2020 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction of incorporation) (Co |
|
| March 24, 2020 |
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Update •U. |
|
| February 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Black Diamond Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 09203E105 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 |
|
| February 13, 2020 |
EX-99.1 Exhibit 1 Joint Filing Agreement The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock of Black Diamond Therapeutics, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D. February 13, 2020 Versant Venture Capital VI, L.P. By: Versant Ventures VI GP, L.P. |
|
| February 13, 2020 |
BDTX / Black Diamond Therapeutics, Inc. / Boxer Capital, LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Black Diamond Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 09203E105 (CUSIP Number) February 3, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 13, 2020 |
EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G with respect to the Common Stock of Black Diamond Therapeutics, Inc., par value $0.0001, is, and any amendments thereto executed by each of us shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, |
|
| February 13, 2020 |
SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* Black Diamond Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 09203E105 (CUSIP Number) |
|
| February 5, 2020 |
BDTX / Black Diamond Therapeutics, Inc. / RA Capital Management, LLC - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response… 10.4 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Black Diamond Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 09203E105 (CUSIP Num |
|
| February 5, 2020 |
CUSIP No. 09203E105 13D Exhibit 1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of February 05, 2020, is by and among RA Capital Management, L.P., Peter Kolchinsky, and Rajeev Shah (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13G and/or |
|
| February 3, 2020 |
EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF BLACK DIAMOND THERAPEUTICS, INC. (the “Corporation”) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, da |
|
| February 3, 2020 |
EX-3.1 Exhibit 3.1 FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BLACK DIAMOND THERAPEUTICS, INC. Black Diamond Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Black Diamond Therapeutics, Inc. The date of the filing of its original Certificate of Incorp |
|
| February 3, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2020 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39200 81-4254660 (State or other jurisdiction of incorporatio |
|
| February 3, 2020 |
BDTX / Black Diamond Therapeutics, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| January 30, 2020 |
424B4 Table of Contents File pursuant to Rule 424(b)(4) Registration No. 333-235789 Prospectus 10,586,316 shares Common stock This is our initial public offering of our common stock. We are offering 10,586,316 shares of common stock. Prior to this offering, there has been no public market for our shares. The initial public offering price is $19.00 per share. Our common stock has been approved for |
|
| January 30, 2020 |
S-8 As filed with the Securities and Exchange Commission on January 30, 2020 Registration No. |
|
| January 29, 2020 |
As filed with the Securities and Exchange Commission on January 29, 2020. As filed with the Securities and Exchange Commission on January 29, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Black Diamond Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 81-4254660 (State or other jurisdiction of incorporation or organ |
|
| January 27, 2020 |
BDTX / Black Diamond Therapeutics, Inc. CORRESP - - CORRESP J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Jefferies LLC 520 Madison Avenue New York, New York 10022 Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 January 27, 2020 United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4561 100 F Street, N.E. Washington, D.C. 20549 Attention: Sonia Bednarowski Dietrich K |
|
| January 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 BLACK DIAMOND THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 81-4254660 (State of incorporation or organization) (I.R.S. Employer Identification No.) 139 Main St |
|
| January 27, 2020 |
BDTX / Black Diamond Therapeutics, Inc. CORRESP - - CORRESP VIA EDGAR January 27, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance Mail Stop 4561 100 F Street, N.E. Washington, D.C. 20549 Attn: Sonia Bednarowski Dietrich King Re: Black Diamond Therapeutics, Inc. AccelerationRequest for Registration Statement on Form S-1 File No. 333-235789 Requested Date: January 29, 2020 Requested Time: 4:00 p.m. Eastern Standard Time D |
|
| January 21, 2020 |
Exhibit 10.4 BLACK DIAMOND THERAPEUTICS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Black Diamond Therapeutics, Inc. 2020 Employee Stock Purchase Plan (the “Plan”) is to provide eligible employees of Black Diamond Therapeutics, Inc. (the “Company”) and each Designated Company (as defined in Section 11) with opportunities to purchase shares of the Company’s common stock, par value $0 |
|
| January 21, 2020 |
Exhibit 3.2 CERTIFICATE OF AMENDMENT TO THE THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BLACK DIAMOND THERAPEUTICS, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Black Diamond Therapeutics, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?DGCL?), d |
|
| January 21, 2020 |
Table of Contents As filed with the Securities and Exchange Commission on January 21, 2020. |
|
| January 21, 2020 |
Form of Underwriting Agreement Exhibit 1.1 BLACK DIAMOND THERAPEUTICS, INC. [?] Shares of Common Stock Underwriting Agreement [?], 2020 J.P. Morgan Securities LLC Jefferies LLC Cowen and Company, LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Cowen and Compa |
|
| January 21, 2020 |
BDTX / Black Diamond Therapeutics, Inc. CORRESP - - CORRESP January 21, 2020 VIA EDGAR AND FEDERAL EXPRESS United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4561 100 F Street, N. |
|
| January 21, 2020 |
Exhibit 10.2 BLACK DIAMOND THERAPEUTICS, INC. 2020 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan (the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Black Diamond Therapeutics, Inc. (t |
|
| January 13, 2020 |
BDTX / Black Diamond Therapeutics, Inc. CORRESP - - CORRESP Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 FOIA CONFIDENTIAL TREATMENT REQUEST The entity requesting confidential treatment is Black Diamond Therapeutics, Inc. 139 Main Street, Suite 301 Cambridge, MA 02142 Telephone: 617-252-848 CERTAIN PORTIONS OF THIS LETTER AS FILED VIA EDGAR HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFID |
|
| January 3, 2020 |
Exhibit 4.1 SECOND AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT THIS SECOND AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT (this ?Agreement?), is made as of November 25, 2019, by and among Black Diamond Therapeutics, Inc., a Delaware corporation (the ?Company?), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an ?Investor.? RECITALS WH |
|
| January 3, 2020 |
Table of Contents As filed with the Securities and Exchange Commission on January 3, 2020. |
|
| January 3, 2020 |
Exhibit 10.11 139 MAIN STREET CAMBRIDGE, MASSACHUSETTS LEASE SUMMARY SHEET Execution Date: March 27, 2019 Tenant: Black Diamond Therapeutics, Inc., a Delaware corporation Tenant?s Mailing Address 25 Health Sciences Drive Prior to Occupancy: Suite 105 Stony Brook, NY 11790 Landlord: MIT 139 Main Street Leasehold LLC, a Massachusetts limited liability company Building: 139 Main Street, Cambridge, Ma |
|
| January 3, 2020 |
Exhibit 3.5 AMENDED AND RESTATED BY-LAWS OF BLACK DIAMOND THERAPEUTICS, INC. (the ?Corporation?) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and |
|
| January 3, 2020 |
Exhibit 3.3 FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BLACK DIAMOND THERAPEUTICS, INC. Black Diamond Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: 1. The name of the Corporation is Black Diamond Therapeutics, Inc. The date of the filing of its original Certificate of Incorporation |
|
| January 3, 2020 |
Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Incorporation Black Diamond Therapeutics (Canada) Inc. Canada Black Diamond Therapeutics Security Corporation Massachusetts |
|
| January 3, 2020 |
Letter of Adeptus Partners, LLC, Independent Public Accountants EXHIBIT 16.1 Adeptus Partners, LLC Accountants | Advisors 733 Route 35 North Ocean, NJ 07712 phone 732.745.8800 fax 732.663.0090 www.AdeptusCPAs.com December 13, 2019 Securities and Exchange Commission 100 F. Street, N.E. Washington, D.C. 20549 Commissioners: We have read the section under the heading ?Change in Our Independent Accounting Firm? included in the Registration Statement on Form S-l of |
|
| January 3, 2020 |
Exhibit 10.8 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made between Black Diamond Therapeutics, Inc., a Delaware corporation (the ?Company?), and Brent Hatzis-Schoch, J.D. (the ?Executive?) and is effective as of the closing of the Company?s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of |
|
| January 3, 2020 |
Exhibit 10.12 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. SERVICES AGREEMENT THIS SERVICES AGREEMENT (this ?Agreement?), effective as of 15th March, 2017 (the ?Effective Date?), is by |
|
| January 3, 2020 |
Exhibit 10.1 BLACK DIAMOND THERAPEUTICS, INC. 2017 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN (Originally adopted March 14, 2017, as amended and restated December 21, 2018) 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Black Diamond Therapeutics, Inc. 2017 Employee, Director and Consultant Equity Incentive Pla |
|
| January 3, 2020 |
Exhibit 10.9 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made between Black Diamond Therapeutics, Inc., a Delaware corporation (the ?Company?), and Thomas Leggett (the ?Executive?) and is effective as of the closing of the Company?s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as am |
|
| January 3, 2020 |
Exhibit 4.3 THIS WARRANT AND THE UNDERLYING SECURITIES AND THE SECURITIES, IF ANY, ISSUABLE UPON THE CONVERSION OF SUCH SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND AP |
|
| January 3, 2020 |
Exhibit 10.5 BLACK DIAMOND THERAPEUTICS, INC. [FORM OF] OFFICER INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made as of [Date] by and between Black Diamond Therapeutics, Inc., a Delaware corporation (the ?Company?), and [Officer Name] (?Indemnitee?). 1 RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Inde |
|
| January 3, 2020 |
Exhibit 10.10 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made between Black Diamond Therapeutics, Inc., a Delaware corporation (the ?Company?), and Christopher D. Roberts, Ph.D. (the ?Executive?) and is effective as of the closing of the Company?s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Ac |
|
| January 3, 2020 |
Exhibit 10.6 BLACK DIAMOND THERAPEUTICS, INC. [FORM OF] DIRECTOR INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made as of [Date] by and between Black Diamond Therapeutics, Inc., a Delaware corporation (the ?Company?), and [Director Name] (?Indemnitee?). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Inde |
|
| January 3, 2020 |
By-laws of the Registrant, as currently in effect Exhibit 3.4 BYLAWS OF ASET THERAPEUTICS, INC. (THE ?CORPORATION?) ARTICLE I Stockholders SECTION 1. Annual Meetings. The annual meeting of the stockholders of the Corporation for the purpose of electing directors and for the transaction of such other business as may be brought before the meeting shall be held, in each year on such day, at such time and such place within or without the State of Del |
|
| January 3, 2020 |
Third Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect Exhibit 3.1 THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BLACK DIAMOND THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Black Diamond Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HE |
|
| January 3, 2020 |
Exhibit 10.7 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made between Black Diamond Therapeutics, Inc., a Delaware corporation (the ?Company?), and David M. Epstein, Ph.D. (the ?Executive?) and is effective as of the closing of the Company?s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 19 |
|
| January 3, 2020 |
Exhibit 4.2 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK PAR VALUE $0.0001 COMMON STOCK Certificate Number ZQ00000000 BLACK DIAMOND THERAPEUTICS, INC. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE Shares 000000 000000 000000 000000 000000 THIS CERTIFIES THAT Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Alexander David Sample Mr. Al |
|
| January 3, 2020 |
Exhibit 10.3 BLACK DIAMOND THERAPEUTICS, INC. SENIOR EXECUTIVE CASH INCENTIVE BONUS PLAN 1. Purpose This Senior Executive Cash Incentive Bonus Plan (the ?Incentive Plan?) is intended to provide an incentive for superior work and to motivate eligible executives of Black Diamond Therapeutics, Inc. (the ?Company?) and its subsidiaries toward even higher achievement and business results, to tie their |
|
| December 13, 2019 |
FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION BLACK DIAMOND THERAPEUTICS, INC. Exhibit 3.3 FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BLACK DIAMOND THERAPEUTICS, INC. Black Diamond Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: 1. The name of the Corporation is Black Diamond Therapeutics, Inc. The date of the filing of its original Certificate of Incorporation |
|
| December 13, 2019 |
AMENDED AND RESTATED BLACK DIAMOND THERAPEUTICS, INC. (the “Corporation”) ARTICLE I Exhibit 3.5 AMENDED AND RESTATED BY-LAWS OF BLACK DIAMOND THERAPEUTICS, INC. (the ?Corporation?) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these By-laws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Board of Directors, which time, date and |
|
| December 13, 2019 |
EXHIBIT 16.1 Adeptus Partners, LLC Accountants | Advisors 733 Route 35 North Ocean, NJ 07712 phone 732.745.8800 fax 732.663.0090 www.AdeptusCPAs.com December 13, 2019 Securities and Exchange Commission 100 F. Street, N.E. Washington, D.C. 20549 Commissioners: We have read the section under the heading ?Change in Our Independent Accounting Firm? included in the Registration Statement on Form S-l of |
|
| December 13, 2019 |
BLACK DIAMOND THERAPEUTICS, INC. [FORM OF] OFFICER INDEMNIFICATION AGREEMENT Exhibit 10.5 BLACK DIAMOND THERAPEUTICS, INC. [FORM OF] OFFICER INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made as of [Date] by and between Black Diamond Therapeutics, Inc., a Delaware corporation (the ?Company?), and [Officer Name] (?Indemnitee?). 1 RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Inde |
|
| December 13, 2019 |
BLACK DIAMOND THERAPEUTICS, INC. [FORM OF] DIRECTOR INDEMNIFICATION AGREEMENT EX-10.6 7 filename7.htm Exhibit 10.6 BLACK DIAMOND THERAPEUTICS, INC. [FORM OF] DIRECTOR INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of [Date] by and between Black Diamond Therapeutics, Inc., a Delaware corporation (the “Company”), and [Director Name] (“Indemnitee”). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified i |
|
| December 13, 2019 |
SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT Exhibit 4.1 SECOND AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT THIS SECOND AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT (this ?Agreement?), is made as of November 25, 2019, by and among Black Diamond Therapeutics, Inc., a Delaware corporation (the ?Company?), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an ?Investor.? RECITALS WH |
|
| December 13, 2019 |
Exhibit 3.1 THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BLACK DIAMOND THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Black Diamond Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HE |
|
| December 13, 2019 |
Table of Contents FOIA CONFIDENTIAL TREATMENT REQUESTED As confidentially submitted to the Securities and Exchange Commission on December 13, 2019 as Amendment No. |
|
| October 30, 2019 |
BDTX / Black Diamond Therapeutics, Inc. DRSLTR - - DRSLTR October 30, 2019 VIA EDGAR AND FEDERAL EXPRESS United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4561 100 F Street, N. |
|
| October 30, 2019 |
Table of Contents FOIA CONFIDENTIAL TREATMENT REQUESTED As confidentially submitted to the Securities and Exchange Commission on October 30, 2019 as Amendment No. |
|
| October 7, 2019 |
BLACK DIAMOND THERAPEUTICS, INC. Exhibit 10.1 BLACK DIAMOND THERAPEUTICS, INC. 2017 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN (Originally adopted March 14, 2017, as amended and restated December 21, 2018) 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Black Diamond Therapeutics, Inc. 2017 Employee, Director and Consultant Equity Incentive Pla |
|
| October 7, 2019 |
Exhibit 10.12 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. SERVICES AGREEMENT THIS SERVICES AGREEMENT (this ?Agreement?), effective as of 15th March, 2017 (the ?Effective Date?), is by |
|
| October 7, 2019 |
139 MAIN STREET CAMBRIDGE, MASSACHUSETTS LEASE SUMMARY SHEET Exhibit 10.11 139 MAIN STREET CAMBRIDGE, MASSACHUSETTS LEASE SUMMARY SHEET Execution Date: March 27, 2019 Tenant: Black Diamond Therapeutics, Inc., a Delaware corporation Tenant?s Mailing Address 25 Health Sciences Drive Prior to Occupancy: Suite 105 Stony Brook, NY 11790 Landlord: MIT 139 Main Street Leasehold LLC, a Massachusetts limited liability company Building: 139 Main Street, Cambridge, Ma |
|
| October 7, 2019 |
BYLAWS ASET THERAPEUTICS, INC. (THE “CORPORATION”) ARTICLE I EX-3.4 2 filename2.htm Exhibit 3.4 BYLAWS OF ASET THERAPEUTICS, INC. (THE “CORPORATION”) ARTICLE I Stockholders SECTION 1. Annual Meetings. The annual meeting of the stockholders of the Corporation for the purpose of electing directors and for the transaction of such other business as may be brought before the meeting shall be held, in each year on such day, at such time and such place within or w |
